OncoC4 to Present Cesalatamig Trial Results in Phoenix
The company will share Phase 1/2 clinical trial findings on November 7, 2026, at a major cancer immunotherapy meeting.
Updated on Oct. 29, 2026 in Cancer
OncoC4 will present new clinical trial results for its PD-1/VEGF bispecific antibody, cesalatamig, on November 7, 2026. The presentation is scheduled for the 41st Annual Meeting of the Society for Immunotherapy of Cancer in Phoenix.
Why it matters
The presentation highlights progress for the drug, which received U.S. FDA Fast Track designation in September 2026 to accelerate its development. These findings from the ongoing BiPAVE-001 trial provide new insights into the efficacy and potential of this dual-action treatment.
The clinical trial results for cesalatamig, identified by abstract number 1187, will be presented at the Society for Immunotherapy of Cancer annual meeting. The drug is currently being tested in the ongoing Phase 1/2 BiPAVE-001 trial.
The players
OncoC4
A biotechnology company headquartered in Rockville, Maryland, focused on the development of novel cancer immunotherapies.
Dr. Kai He
A researcher tasked with presenting clinical findings from the ongoing BiPAVE-001 study.
Society for Immunotherapy of Cancer
A professional medical organization that hosts an annual meeting to advance the science of cancer immunotherapy.
The details
Dr. Kai He is scheduled to present the BiPAVE-001 clinical trial findings as an oral abstract. The presentation will take place during Clinical Oral Abstract Session 2, beginning at 1:45 PM MST.
Timeline
September 2026: The U.S. FDA granted cesalatamig Fast Track designation.
October 29, 2026: OncoC4 announced the upcoming abstract presentation.
November 7, 2026: Dr. Kai He will present findings at the Society for Immunotherapy of Cancer meeting at 1:45 PM MST.
Health Landscape
The development of cesalatamig follows the pattern set by the FDA Fast Track designation program, which aims to facilitate the review of drugs intended to treat serious conditions. This presentation marks a critical step in sharing data for a therapy fast-tracked to meet urgent patient needs.
The clinical findings provide necessary updates for patients and providers following the drug through the research pipeline. As the trial progresses, the outcomes may eventually influence future treatment availability for individuals seeking new immunotherapy options.
The takeaway
Clinical trial data presentations are essential milestones in the multi-year process of bringing experimental cancer drugs to market. Readers should monitor these professional society meetings for the most accurate and up-to-date information on emerging medical treatments.
Further reading
For more information on the latest developments, visit the Cancer section.
